Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases

This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still has a resectable primary intrahepatic tumor. Participants will be randomly assigned to receive either primary tumor resection followed by protocol-allowed first-line immune-based systemic therapy or systemic therapy alone. The primary outcome is overall survival. Secondary outcomes include progression-free survival, objective response rate, disease control rate, immune-related adverse events, postoperative complications, and quality of life.

NCT Number	NCT07537959
Lead Sponsor	Tongji Hospital
Conditions	Hepatocellular Carcinoma (HCC), Metastasis
Enrollment	280 participants
Start Date	2026-04-30
Primary Completion	2026-04-30 (estimated)
Study Completion	2031-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-17